{"product_id":"lucitivo-tivozanib","title":"LuciTivo (Tivozanib)","description":"\u003ch2\u003eAbout Tivozanib\u003c\/h2\u003e\u003cp\u003eTivozanib  is a medication used for the treatment of advanced renal cell carcinoma (kidney cancer).\u003csup id=\"cite_ref-FDA_tivozanib_3-1\" class=\"reference\"\u003e\u003c\/sup\u003eIt is an oral VEGF receptor tyrosine kinase inhibitor.\u003c\/p\u003e\u003ch3\u003eRenal Cell Carcinoma\u003c\/h3\u003e\u003cp\u003eIndicated for relapsed or refractory advanced renal cell carcinoma in patients previously treated with ≥2 systemic therapies\u003c\/p\u003e\u003cp\u003e1.34 mg PO qDay on Days 1-21 of repeated 28-day cycles\u003c\/p\u003e\u003cp\u003eContinue until disease progression or unacceptable toxicity\u003c\/p\u003e\u003ch3\u003eDosage Modifications\u003c\/h3\u003e\u003cp\u003eIf dose modifications are required for adverse reactions, reduce to 0.89 mg qDay for 21 days followed by 7 days off treatment\u003c\/p\u003e\u003cp\u003eInitiate medical management for diarrhea, nausea, or vomiting prior to dose interruption or reduction\u003c\/p\u003e\u003ch4\u003eHypertension\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003e\n\u003ch5\u003eGrade 3\u003c\/h5\u003e\n\u003cul\u003e\n\u003cli\u003eWithhold for persistent Grade 3 despite optimal antihypertensive therapy\u003c\/li\u003e\n\u003cli\u003eResume at reduced dose when hypertension controlled at Grade ≤2\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ch5\u003eGrade 4\u003c\/h5\u003e\n\u003cul\u003e\u003cli\u003ePermanently discontinue\u003c\/li\u003e\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003eCardiac failure\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003e\n\u003ch5\u003eGrade 3\u003c\/h5\u003e\n\u003cul\u003e\n\u003cli\u003eWithhold until improves to Grade ≤1 or baseline\u003c\/li\u003e\n\u003cli\u003eResume at reduced dose or discontinue depending on severity and persistence\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ch5\u003eGrade 4\u003c\/h5\u003e\n\u003cul\u003e\u003cli\u003ePermanently discontinue\u003c\/li\u003e\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003eArterial thromboembolic events or reverse posterior leukoencephalopathy syndrome (RPLS)\u003c\/h4\u003e\u003cul\u003e\u003cli\u003eAny grade: Permanently discontinue\u003c\/li\u003e\u003c\/ul\u003e\u003ch4\u003eHemorrhagic events\u003c\/h4\u003e\u003cul\u003e\u003cli\u003eGrade 3 or 4: Permanently discontinue\u003c\/li\u003e\u003c\/ul\u003e\u003ch4\u003eProteinuria\u003c\/h4\u003e\u003cul\u003e\u003cli\u003e\n\u003ch5\u003e2 grams or greater proteinuria in 24 hr\u003c\/h5\u003e\n\u003cul\u003e\n\u003cli\u003eWithhold until less than or equal to 2 grams of proteinuria per 24 hr\u003c\/li\u003e\n\u003cli\u003eResume at a reduced dose\u003c\/li\u003e\n\u003cli\u003ePermanently discontinue for nephrotic syndrome\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\u003c\/ul\u003e\u003ch4\u003eOther adverse reactions\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003e\n\u003ch5\u003ePersistent or intolerable Grade 2 or 3 OR Grade 4 laboratory abnormality\u003c\/h5\u003e\n\u003cul\u003e\u003cli\u003eWithhold until improves to Grade ≤1 or baseline; resume at reduced dose\u003c\/li\u003e\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ch5\u003eGrade 4\u003c\/h5\u003e\n\u003cul\u003e\u003cli\u003ePermanently discontinue\u003c\/li\u003e\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003eRenal impairment\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eMild-to-severe (CrCl 15-89 mL\/min): No dosage modifications\u003c\/li\u003e\n\u003cli\u003eEnd-stage renal disease: Recommend dose not established\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003eHepatic impairment\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eMild (total bilirubin [TB] ≤1.5x ULN with any AST): No dosage adjustment necessary\u003c\/li\u003e\n\u003cli\u003eModerate (TB \u0026gt;1.5 to 3x ULN with any AST): Reduce to 0.89 mg qDay\u003c\/li\u003e\n\u003cli\u003eSevere (TB 3 to 10x ULN with any AST): Not established\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch3\u003eDosing Considerations\u003c\/h3\u003e\u003cp\u003eVerify pregnancy in females of reproductive potential before initiation\u003c\/p\u003e","brand":"Lucius Pharmaceuticals (Lao) Co., Ltd","offers":[{"title":"Default Title","offer_id":44797954293803,"sku":"RL3120250101","price":0.0,"currency_code":"AMD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0701\/3528\/3755\/files\/2024-12-0821.jpg?v=1787022221","url":"https:\/\/xomeds.com\/products\/lucitivo-tivozanib","provider":"XOMEDS","version":"1.0","type":"link"}